动态EASIX评分可紧密预测异基因造血细胞移植后的非复发死亡
研究纳入2008至2016年间接受异基因造血细胞移植的509例成人,连续计算EASIX至移植后1年。EASIX评分在移植后第+8天达峰,第+180天左右对非复发死亡的区分度最高(一致性指数=0.85),且两种移植平台间随时间变化的预后影响不同。
要点
- EASIX评分在移植后第+8天达峰,之后下降但仍高于移植前基线。
- 第+180天左右EASIX对非复发死亡的区分度最高,一致性指数=0.85。
- 未修饰移植者的EASIX评分随时间高于CD34+ selected移植者。
核心结论
- EASIX评分是动态的,纵向分析时与非复发死亡的 concordance 随时间变化,且两种移植平台间模式不同。
- 与移植前评估相比,移植后EASIX评分可能更好地预测非复发死亡风险,因为患者会累积额外的内皮损伤和毒性。
研究设计与样本
- 评估2008至2016年间接受减低强度未修饰(N=149,29%)或清髓性ex vivo CD34+ selected异基因造血细胞移植(N=306,71%)的509例成人。
- 未修饰移植者接受基于他克莫司的移植物抗宿主病预防,CD34+ selected者未接受计划性免疫抑制。
- EASIX(乳酸脱氢酶×肌酐/血小板计数)连续计算至移植后1年,所有EASIX变量采用以2为底的对数(log2)转换以减少偏态。
主要发现
- 总共360例(71%)接受CD34+ selected移植,149例(29%)接受未修饰移植。
- 所有患者中EASIX评分快速升高,第+8天达峰,之后快速下降至第+33天,此后逐渐下降但仍高于移植前基线。
- 未修饰移植者的EASIX评分随时间高于CD34+ selected移植者。
- 两种平台中EASIX对非复发死亡的区分度均在第+180天左右最高(一致性指数=0.85),但EASIX在各时间点的预后影响在两种平台间不同。
- 男性平均EASIX评分更高(平均log2 +0.52),发生2至4级移植物抗宿主病者更高(+0.81),接受相合供者者低于不相合供者(-0.81,所有P<.01)。
临床怎么用
- 与移植前评估相比,移植后EASIX评分可能更好地预测非复发死亡风险(作者认为)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Endothelial activation and stress index (EASIX) predicts nonrelapse mortality (NRM) when assessed before hematopoietic cell transplantation (HCT). We sought to determine whether changes in EASIX after HCT may be an informative marker of NRM. We evaluated 509 adults who underwent reduced intensity, unmodified (N = 149, 29%), or myeloablative ex vivo CD34+-selected allogeneic HCT (allo-HCT) (N = 306, 71%) between 2008 and 2016. Patients who underwent unmodified allo-HCT received tacrolimus-based graft-versus-host disease (GVHD) prophylaxis, whereas CD34+-selected patients received no planned immunosuppression. EASIX (lactate dehydrogenase × creatinine/platelet count) was calculated continuously until 1-year after HCT. Log transformation using base 2 (log2) was applied to all EASIX variables to reduce skew. In total, 360 patients (71%) received CD34+-selected and 149 (29%) unmodified allo-HCT. Among all patients, EASIX scores increased rapidly, peaked at day +8, then declined rapidly until day +33. Thereafter, scores declined gradually but remained above the pre-HCT baseline. In unmodified HCT, scores appeared higher over time than in CD34+-selected patients. EASIX discrimination of NRM was highest around day +180 (concordance index = 0.85) in both platforms, but the prognostic impact of EASIX across time points differed between the 2 platforms. Mean EASIX scores were higher in men (mean log2 +0.52) and in patients who developed grade 2 to 4 GVHD (+0.81) and lower in patients who received matched vs mismatched donors (-0.81, all P < .01). EASIX scores are dynamic and variably concordant with NRM when analyzed longitudinally, and patterns differ between HCT platforms. Compared to pre-HCT evaluation, post-HCT EASIX scores may better predict risk of NRM as patients acquire additional endothelial injury and toxicities.
引用
- Nawas MT, Sanchez-Escamilla M, Devlin SM, et al. Dynamic EASIX scores closely predict nonrelapse mortality after allogeneic hematopoietic cell transplantation. Blood Adv. 2022. PMID: 35977079. doi:10.1182/bloodadvances.2022007381
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。